Skip to content
OpenCapital
Get started

Capricor Therapeutics CAPR Q4 2025 Annual earnings

Reported March 12, 2026 · After market close

Revenue-Miss by $525.0KDiluted EPS-$0.62Miss by $0.11
Revenue estimate$525.0K
EPS estimate-$0.51

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$2.1M
EPS estimate-$0.58

Financials

Q4 2025

Income statement

See full
Revenue--100%
Operating income-$29.2M-279%
Net income-$30.2M-324%
EPS (diluted)-$0.62-464%

Balance sheet

See full
Cash & equivalents$287.8M+2,450%
Total debt$14.5M+901%
Total equity$305.8M+110%
Total assets$355.9M+109%

Cash flow

See full
Operating cash flow-$23.6M-59.3%
CapEx$1.7M+241%
Free cash flow-$25.2M-65.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.57B+150%
Enterprise value$1.3B+110%

Returns & leverage

See full
Return on equity-46.6%-1.5pp
Debt / equity0×0.0×
Current ratio9×+1.2×

Versus estimates

Revenue

Q4 2024$11.1MBeat by $5.6M

Diluted EPS

Q1 2026-$0.59Miss by $0.04
Q4 2025-$0.62Miss by $0.11
Q3 2025-$0.54In lineQ2 2025-$0.57Miss by $0.09Q1 2025-$0.53Miss by $0.20Q4 2024-$0.16Beat by $0.15

Ask the moment Capricor Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Capricor Therapeutics report Q4 2025 earnings?
Capricor Therapeutics (CAPR) reported Q4 2025 earnings on March 12, 2026 after market close.
What were Capricor Therapeutics's Q4 2025 revenue and EPS?
Capricor Therapeutics reported revenue of - and diluted EPS of $-0.62 for Q4 2025.
Did Capricor Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $525.0K by $525.0K. EPS missed the consensus estimate of $-0.51 by $0.11.
How did Capricor Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $11.1M a year earlier and diluted EPS declined 287.5% from $-0.16.
Where can I find Capricor Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-025657) and the 10-K periodic report (0001104659-26-029580) directly on SEC EDGAR. The filing index links above go to sec.gov.